Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial.

ABSTRACT:

Background

Melatonin has been known as an anti-inflammatory agent and immune modulator that may address progressive pathophysiology of coronavirus disease 2019 (COVID-19).

Aim of the study

To evaluate the clinical efficacy of adjuvant, use of melatonin in patients with COVID-19.

Methods

This single-center, double-blind, randomized clinical trial included 74 hospitalized patients with confirmed mild to moderate COVID-19 at Baqiyatallah Hospital in Tehran, Iran, from April 25, 2020-June 5, 2020. Patients were randomly assigned in a 1:1 ratio to receive standard of care and standard of care plus melatonin at a dose of 3 mg three times daily for 14 d. Clinical characteristics, laboratory, and radiological findings were assessed and compared between two study groups at bas

SUBMITTER: Farnoosh G 

PROVIDER: S-EPMC8220995 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature